- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06327789
Trunk Control and Disability in Persons With Multiple Sclerosis
March 22, 2024 updated by: ARZUCAN TOKSAL, Zonguldak Bulent Ecevit University
The Relationship Between Trunk Control and Disability in Persons With Early Relapsing Multiple Sclerosis
This study aims to investigate the relationship between physical disability and trunk control, balance, and pedobarographic parameters in persons with Relapsing Remitting Multiple Sclerosis (RRMS) who have a low Expanded Disability Status Scale (EDSS) score.
Twenty-three RRMS patients with an age range of 18-50 years, EDSS score ≤ 3 were included in this study.
The patients' level of disability (EDSS), trunk control )Trunk Impairment Scale - TIS), lower extremity functionality (Timed 25-Foot Walk Test - T25FW), upper extremity functionality (Nine Hole Peg Test- 9HPT), balance (Biodex Balance System) and gait (Zebris® FDM 2) were evaluated.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
23
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zonguldak, Turkey
- Zonguldak Bülent Ecevit University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
diagnosed with relapsing-remitting multiple sclerosis by an experienced neurologist
Description
Inclusion Criteria:
- 18-50 years old,
- diagnosed with RRMS by an experienced neurologist
- EDSS score ≤ 3
Exclusion Criteria:
- orthopedic or sensory additional problems in the lower extremity
- who had an interventional procedure in the last six months, and had an attack in the last three months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Multiple Sclerosis
Patients who were 18-50 years old, diagnosed with RRMS by a experienced neurologist, and with an EDSS score ≤ 3 were included in this study.
Patients with orthopedic or sensory additional problems in the lower extremity, who had an interventional procedure in the last six months, and had an attack in the last three months were excluded from the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Expanded Disability Status Scale (EDSS)
Time Frame: up to 8 weeks
|
EDSS was used to determine the patients' level of disability.
EDSS is most commonly used to assess the level of disability in persons with MS.
In this scale pyramidal, cerebral, cerebellar, brainstem, visual and sensory subparameters are evaluated it consists of ordinal rating system ranging from 0 (normal neurological status) to 10 (death due to MS) in 0.5 increments interval (when reaching EDSS 1).
The lower scale values of the EDSS measure impairments based on the neurological examination, while the upper range of the scale (> EDSS 6) measures handicaps of patients with MS.
The determination of EDSS 4 - 6 is heavily dependent on aspects of walking ability
|
up to 8 weeks
|
|
Trunk Impairment Scale (TIS)
Time Frame: up to 8 weeks
|
This scale used to evaluate the trunk control of the participants, TIS contains static sitting balance, dynamic sitting balance, and coordination.
The total score of this scale is from 0 to 23 and a high score indicates better trunk control.
The patients were placed in the standard sitting position for the test and the parameters were applied.
Standart position is such that the knees are flexed at 90 degrees, without back support, with the hands and forearms on the thighs and the feet in contact with the ground.
|
up to 8 weeks
|
|
Biodex Balance System (BBS) (MedicalSystems, Shirley, NY, USA)
Time Frame: up to 8 weeks
|
This system is a multiaxial device that objectively measures and records a patient's ability to stabilize the involved joint under dynamic stress.
The BBS measures, in degrees, the tilt about each axis during dynamic conditions and calculates a medial-lateral stability index (MLSI), anterior-posterior stability index (APSI), and an overall stability index (OSI).
These indexes represent fluctuations around a zero point established before testing when the platform is stable.
A high score in the all parameters indicates poor balance.
The test was performed in 3 repetitions, each lasting 20 seconds, with a 10-second rest period in between, under different conditions, including eyes open-closed, firm-foam surface, and static-dynamic surface.
The average of the three repetitions was calculated automatically by the device
|
up to 8 weeks
|
|
Step Length (cm)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Stride Length (cm)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Step Width (cm)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Cadence (steps/min)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Velocity (m/s)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Step time (s)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Stride time (s)
Time Frame: up to 8 weeks
|
The temporal-spatial characteristics of gait were assessed through the utilization of dynamic pedobarography.
Dynamic pedobarographic analysis was performed with the implementation of a pressure platform (Zebris® FDM 2, dimensions 212.2x60.5x2.5 cm, Zebris Medical GmbH, Germany) positioned at the center of an 8-meter walking path.
Patients completed the gait cycle three times, once for forward and once for backward gait, while barefoot.
|
up to 8 weeks
|
|
Timed 25-Foot Walk Test (T25FW)
Time Frame: up to 8 weeks
|
This test is designed for the evaluation of lower extremity functions.Initiated at the participant's first step, the test concludes upon reaching the finish line.
The participants are instructed to walk as expeditiously as feasible within a specified time frame without running.
The duration taken to traverse the 25-foot distance, both for the outbound and return segments, is documented, and subsequently, the average of these two durations is calculated.
|
up to 8 weeks
|
|
Nine-Hole Peg Test (9HPT)
Time Frame: up to 8 weeks
|
It is a short, standardized, quantitative test used to evaluate upper extremity function.
In the test, patients are asked to pick up nine wooden pegs from a platform as quickly as possible and then place them back into the holes.In our study, the test was conducted twice for both the dominant and non-dominant hands, and the average completion time was recorded.
|
up to 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Bilge Piri Çınar, Samsun University
- Principal Investigator: Gungor Beyza Ozvar Senoz, Yuksek Ihtisas University
- Principal Investigator: Hasret Uçar, Zonguldak Bülent Ecevit University
- Principal Investigator: Serkan Özakbaş, Dokuz Eylül University
- Principal Investigator: Mustafa Açıkgöz, Zonguldak Bülent Ecevit University
- Principal Investigator: Nursena Ceylan, Zonguldak Bülent Ecevit University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 21, 2021
Primary Completion (Actual)
December 25, 2021
Study Completion (Actual)
February 21, 2022
Study Registration Dates
First Submitted
March 13, 2024
First Submitted That Met QC Criteria
March 22, 2024
First Posted (Actual)
March 25, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZBEU-MS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain